Drogenabusus in der Schwangerschaft – Risiko für das Kind

Eva Robel-Tillig

doi:10.1055/s-0043-117111

Neonatologie Scan, Inhaltsverzeichnis

Neonatologie Scan 2017; 06(04): 303-313
DOI: 10.1055/s-0043-117111

CME-Fortbildung

Drogenabusus in der Schwangerschaft – Risiko für das Kind

Eva Robel-Tillig

Verantwortlicher Herausgeber dieser Rubrik: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Eva Robel-Tillig, Bamberg.

Abstract

Drogensucht in der Schwangerschaft stellt ein schwerwiegendes Problem dar – sowohl für die werdende Mutter und das ungeborene Kind als auch für die Umgebung der Eltern. Dieser Beitrag geht insbesondere auf Opiat/Opioid- und Methamphetamin-Abusus in der Schwangerschaft ein: auf die jeweilige Symptomatik, die Therapie und die langfristigen Folgen für das Kind und die Eltern.

Schlüsselwörter

Opiat-Abusus - Methamphetamin-Abusus - Entzugssymptomatik - neonatales Abstinenzsyndrom

Volltext

Referenzen

Literatur
1 Ko JY, Wolicki S, Barfield WD. et al. CDC grand Rounds: Public health strategies to prevent neonatal abstinence syndrome. MMWR Morb Mortal Wkly Rep 2017; 66: 242-245
2 Dinger J, Hinner P, Reichert J. et al. Methamphetamine consumption during pregnancy – effects on child health. Pharmacopsychiatry 2017; 50: 107-113
3 Sutter MB, Gopman S, Leeman L. Patient-centered care to address barriers for pregnant women with opioid dependence. Obstet Gynecol Clin North Am 2017; 44: 95-107
4 Krans EE, Patrick SW. Opioid disorders in pregnancy: Health policy and practice in the midst of an epidemic. Obstet Gynecol 2016; 128: 4-10
5 Terplan M, Minkoff H. Neonatal abstinence syndrome and ethical approaches to the identification of pregnant women who use drugs. Obstet Gynecol 2017; 129: 164-167
6 Kohsman MG. Ethical considerations for perinatal toxicology screening. Neonatal Netw 2016; 35: 268-276
7 Palmer KL, Woode KE, Krasowski MD. Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: a retrospective study at an academic medical center. Clin Biochem 2017; 50: 255-261
8 Joya X, Pacifici R, Salat-Battle J. et al. Maternal and neonatal hair and breast milk in the assessment of perinatal exposure to drug abuse. Bioanalysis 2015; 7: 1273-1297
9 Patrick SW, Schiff DM. ; Committee on substance use and prevention. A public health response to opioid use in pregnancy. Pediatrics 2017; 139: pii: e20164070
10 Jones HE, Kaltenbach K, Heil SH. et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 9: 2320-2331
11 Wurst KE, Zedler BK, Joyce AR. et al. A Swedish population-based study of adverse birth outcomes among pregnant women treated with buprenorphine or methadone: preliminary findings. Subst Abuse 2016; 15: 89-97
12 Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol 2015; 39: 561-565
13 Jones HE, Seashore C, Johnson E. et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS Scale. Am J Addict 2016; 25: 370-373
14 Holmes AV, Atwood EC, Whalen B. et al. Rooming in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics 2016; 137: pii: e20152929
15 Newman A, Davies GA, Dow K. et al. Rooming in care for infants of opioid-dependent mothers: implementation and evaluation at a tertiary care hospital. Can Fam Physician 2015; 61: 555-561
16 Howard MB, Schiff DM, Penwill N. et al. Impact of parental presence at infants bedside on neonatal abstinence syndrome. Hosp Pediatr 2017; 7: 63-69
17 Maquire DJ, Taylor S, Armstrong K. et al. Long-term outcomes of infants with neonatal abstinence syndrome. Neonatal Netw 2016; 35: 277-286
18 Gabrhelik R, Nechanska B, Mravcik V. et al. A unique opportunity to study short and long term consequences in children prenatally exposed to illicit drugs and opioid maintenance treatment using Czech and scandinavian registers. Cent Eur J Public Health 2016; 24: 248-251
19 Kittirattanapaiboon P, Srikosai S, Wittayanookulluk A. Methamphetamine use and dependence in vulnerable female populations. Curr Opin Psychiatry 2017; 30: 247-252
20 Sirova J, Kristofikova Z, Vrajova A. et al. Sex dependent changes in striatal dopamine transport in preadolescent rats exposed prenatally and/or postnatally to methamphetamine. Neurochem Res 2016; 41: 1911-1923
21 Rorabaugh BR, Seeley SL, Bui AD. et al. Prenatal methamphetamine differentially alters myocardial sensitivity to ischemic injury in male and female adult hearts. Am J Physiol Heart Circ Physiol 2016; 15: 516-523
22 Mc Donell-Dowling K, Kelly JP. The consequences of prenatal and/or postnatal methamphetamine exposure on neonatal development and behavior in rat offspring. Int J Dev Neurosci 2015; 47: 147-156
23 Dyk JV, Ramnajam V, Church P. et al. Maternal methamphetamine use in pregnancy and long term neurodevelopmental and behavioral effects. J Popul Ther Clin Pharmacol 2014; 21: 185-196
24 Wouldes TA, Lagasse LL, Huestis MA. et al. Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years. Neurotoxicol Teratol 2014; 42: 77-84
25 Kiblawi ZN, Smith LM, La Gasse LL. et al. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: results from the infant development, environment and lifestyle study. J Dev Behav Pediatr 2013; 34: 31-37
26 Eze N, Smith LM, La Gasse LL. et al. School age outcomes following prenatal methamphetamine exposure: 7,5-year follow up from the infant development, environment and lifestyle study. J Pediatr 2016; 170: 34-38